The abioSCOPE®

The first nanofluidic based immunoassay platform

The fastest Sepsis test for the Emergency Room, the ICU and Patient's therapeutic follow-up

Sepsis
The problem

Today, in the hospital environment, it takes more than 24 hours to diagnose and begin anti-biotherapy for a patient that has already developed a case of Sepsis.

This large time-frame is the essential cause of many fatalities in addition to long and highly expensive stays in the ICUs.

Key figures

Sepsis affects more than 26 million persons every year

Mortality increases 8% every hour that the treatment is delayed

Sepsis represents more than $24 billion medical costs in the US

Sepsis
Our Solution

With the abioSCOPE®, the same patient will be identified with a high risk of developing Sepsis in just 5 minutes, leading to an immediate start of the appropriate therapeutic intervention.

We offer a fast, accurate and affordable diagnostic solution - increasing the chances of survival for patients, while decreasing the financial burden.

The abioSCOPE® is also made to support the clinician in determining when to interrupt the anti-biotherapy, and thus reduce the risk of increased resistance to antibiotics.

  • Recognise it earlier
  • Treat it faster
  • Monitor it better
Early diagnosis of sepsis is critical

Abionic has developed the only test allowing the detection of sepsis in 5 minutes and up to 24 hours before the first clinical symptoms appear.

Thanks to a new biomarker, the Pancreatic Stone Protein (PSP), the Abionic PSP test can provide an earlier, faster and more specific solution to detect Sepsis.

We have the potential to save millions of lives.

Could prevent up to 80% of Sepsis deaths

Reduce hospitals expenditures by over $1.5 billions